A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil
Latest Information Update: 29 Jul 2022
At a glance
- Drugs EYN 1601 Eyenovia (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- Acronyms EYE 102
- Sponsors Eyenovia
- 30 Oct 2017 Results presented in an Eyenovia media release.
- 06 Dec 2016 Status changed from recruiting to completed.
- 15 Nov 2016 New trial record